Importantly, data from all three databases indicate that ARPC1A is associated with resistance to gefitinib (Figures 9E), implying that targeting ARPC1A could improve treatment outcomes for gefitinib-resistant cancer patients. The gene discussed is ARPC1A; the disease is cancer.